Recombinant Human BTLA (C-mFc)

Description

EnkiLife provides the Recombinant Human BTLA (C-mFc) protein,aslo know as B- and T-Lymphocyte Attenuator,B- and T-Lymphocyte-Associated Protein,CD272,BTLA, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human B-and T-Lymphocyte Attenuator is produced by our Mammalian expression system and the target gene encoding Lys31-Leu150 is expressed with a mouse IgG1 Fc tag at the C-terminus.Accession:Q7Z6A9-2. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:40.4 KDa. Background:B- and T-Lymphocyte Attenuator (BTLA) is a single-pass type I membrane protein containing 1 Ig-like V-type (immunoglobulin-like) domain. BTLA expression is induced during activation of T cells, and BTLA remains expressed on Th1 cells but not Th2 cells. Like PD1 and CTLA4, BTLA interacts with a B7 homolog, B7H4. However, unlike PD-1 and CTLA-4, BTLA displays T-Cell inhibition via interaction with tumor necrosis family receptors (TNF-R), not just the B7 family of cell surface receptors. BTLA is a lymphocyte inhibitory receptor that inhibits lymphocytes during immune response. BTLA also is a ligand for tumor necrosis factor (receptor) superfamily, member 14 (TNFRSF14), also known as herpes virus entry mediator (HVEM). BTLA-HVEM complexes negatively regulate T-cell immune responses.